Can an antibody boost help transplant patients beat CMV faster?
NCT ID NCT07009548
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial tests whether adding a single dose of CytoGam—a concentrated antibody product against cytomegalovirus (CMV)—to standard antiviral drugs helps clear CMV from the blood faster in solid organ transplant recipients. The study enrolls adults aged 18–75 who have received an organ transplant and have CMV infection. Researchers will measure how quickly the virus disappears, whether antiviral resistance develops, and if CMV comes back after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV), also known as CytoGam, given as a single intravenous dose alongside standard antiviral medication
- What this could lead to
- If effective, adding CytoGam to standard antivirals could speed up CMV clearance, reduce antiviral resistance, and lower recurrence risk in transplant recipients.
- What could go wrong
- This is a small phase 4 trial (45 participants), so results may not apply broadly. The single-dose approach may not provide lasting benefit, and infusion-related reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.